Pegaptanib

SENSORY ORGANS

Key facts

Pegaptanib is a drug catalogued in DrugCentral. It was first approved by the FDA in 2004. DrugCentral lists 1 molecular target, including VEGFA. Recorded indications include Exudative age-related macular degeneration.

• Molecular targets: VEGFA (1 listed in DrugCentral).
• Indications: Exudative age-related macular degeneration.
• ATC code: S01LA03 (Antineovascularisation agents).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Exudative age-related macular degeneration

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Vascular endothelial growth factor A	VEGFA	antagonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2004-12-17	FDA	—	VALEANT PHARMS LLC

ATC classification

ATC code	Therapeutic hierarchy
S01LA03	SENSORY ORGANS › OPHTHALMOLOGICALS › OCULAR VASCULAR DISORDER AGENTS › Antineovascularisation agents

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pegaptanib used for?

DrugCentral lists the following indications for Pegaptanib: Exudative age-related macular degeneration.

How does Pegaptanib work?

Its molecular targets in DrugCentral include VEGFA (antagonist).

When was Pegaptanib first approved?

Pegaptanib was first approved by the FDA in 2004.

Sources

• DrugCentral drug card 4905 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201421 — compound record and bioactivity
• DrugBank DB04895 — drug record
• FDA UNII 2H1PA8H1EN — substance identity
• DailyMed: FDA labels for Pegaptanib — current prescribing information (label search)
• UniProt P15692 (VEGFA) — target protein

How this page is built: methodology · editorial policy & corrections.